SCHEMBL6207559

SCHEMBL6207559

CCCCc1ccc(C(=O)C2CCN(C(=O)OC(C)(C)C)CC2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
STS P08842 7/20 0.45
RECQL P46063 1/20 0.44
PDE4D Q08499 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 1/20 0.43
GLS O94925 1/20 0.42
GPR119 Q8TDV5 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL226425 0.79 STS (0.54) PTPN2PTPN1PTPN6STSRECQL
SCHEMBL228056 0.79 PTPN2 (0.51) PTPN2PTPN1PTPN6STSRECQL
SCHEMBL8613358 0.77 GPR119 (0.48) GLSGPR119
SCHEMBL3850388 0.77 GPR119 (0.49) PTPN2PTPN1PTPN6STSRECQL
SCHEMBL6206003 0.75 MEN1 (0.41) RECQLKMT2AHPGDNPC1ALDH1A1
SCHEMBL5717333 0.75 HDAC1 (0.42) PDE4DPDE4APDE4BPDE4CGLS
SCHEMBL226265 0.74 ALDH1A1 (0.54) PTPN2PTPN1PTPN6STSKMT2A
SCHEMBL27398448 0.72 PRMT5 (0.42) STSGPR119MAPTHTT
SCHEMBL20601309 0.72 KDM4E (0.48) STSGLSGPR119
SCHEMBL16492726 0.71 NAMPT (0.54) PTPN2PTPN1PTPN6PDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 PTPN2 4062/4885PTPN1 4040/4885PTPN6 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.